Treatment strategy for acute uncomplicated urinary tract infections in women


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Urinary tract infections (UTIs) are among the most common infectious diseases. Uncomplicated UTI usually develops in people without obstructive uropathies and structural changes in the kidney and urinary tract in the absence of background diseases. Unreasonable and irrational antibacterial therapy is a factor leading to the chronization of the process. The emergence of resistance of microbial strains to the most commonly used antibiotics causes a range of drugs to treat acute cystitis to be changed. Adequate antibiotic therapy is the cornerstone of successful treatment for acute uncomplicated cystitis. The once-daily antibiotic regimen has many undeniable advantages. Phosphomycin trometamol is a highly effective agent for the elimination of the causative agents of UTI and has a high safety profile.

Full Text

Restricted Access

About the authors

Evgeniy A. Pronkin

Clinical Hospital One Hundred and Twenty-Three, Federal Biomedical Agency of Russia

Email: dr.pronkin@gmail.com
Candidate of Medical Science, Head of the Department of Urology

References

  1. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Федеральные клинические рекомендации. М.; 2017.
  2. Naber K.G., Schito G., Botto H., Paiou J., Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur. Urol. 2008; 54(5): 1164-75.
  3. European Association of Urology. EAU Guidelines urological infections; update 2017; 3.4.1. Available at: www.uroweb.org
  4. Lutay N., Ambite I., Grönberg Hernandez J., Rydström G., Ragnarsdottir B., Puthia M. et al. Bacterial control of host geneexpression through RNA polymerase II. J. Clin. Invest. 2013; 123(6): 2366-79.
  5. Cai T., Mazzoli S., Mondaini N., Meacci F., Nesi G., D'Elia C. et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: To treat or not to treat? Clin. Infect. Dis. 2012; 55(6): 771-7.
  6. Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю., ред. Урология. Клинические рекомендации. М.: ГЭОТАР-Медиа; 2016. 480с.
  7. Köves B., Cai T., Veeratterapillay R., Pickard R., Seisen T., Lam T.B. et al. Benefits and harms of treatment of asymptomatic bacteriuria: a systematic review and meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. Eur. Urol. 2017; 72(6): 865-8.
  8. Зайцев А.В., Тупикина Н.В. Рецидивирующая инфекция мочевых путей - междисциплинарная проблема. Медицинский совет. 2014; 19: 36-44.
  9. Ho P.L., Wong R.C., Yip K.S., Loke S.L., Leung M.S., Mak G.C. et al. Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes. Diagn. Microbiol. Infect. Dis. 2007; 59(4): 439-45.
  10. Gagliotti C., Buttazzi R., Sforza S., Moro M.L.; Emilia-Romagna Antibiotic Resistance Study Group. Resistance to fluoroquinolones and treatment failure/ short-term relapse of community-acquired urinary tract infections caused by Escherichia coli. J. Infect. 2008; 57(3): 179-84.
  11. Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., Athanasiou S. Фосфомицин в сравнении с другими антибиотиками, применяемыми в лечении цистита - мета анализ рандомизированных контролируемых исследований. Экспериментальная и клиническая урология. 2013; 1: 94-102.
  12. Falagas M.E., Roussos N., Gkegkes I.D., Rafailidis P.I., Karageorgopoulos D.E. Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies. Expert Opin. Investig. Drugs. 2009;18(7): 921-44.
  13. Bishop M.C. Uncomplicated urinaru tract infection. EAU Updated Series. 2014; 2(3): 143-50.
  14. Falagas M.E., Kastoris A.C., Karageorgopoulos D.E., Rafailidis P.I. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram negative bacilli: a systematic review of Systematic review 1875 JAC by guest on October 6, 2012. Available at: http://jac.oxfordjournals.org/ Downloaded from microbiological, animal and clinical studies. Int. J. Antimicrob. Agents. 2009; 34(2): 111-20.
  15. Wagenlehner F.M., Thomas P.M., Naber K.G. Fosfomycin trometamol (3.000 mg) in perioperative antibiotic prophylaxis of healthcare-associated infections after endourological interventions: a narrative review. Urol. Int. 2014; 92(2): 125-30.
  16. Палагин И.С., Cухорукова М.В., Гринев А.В., Перепанова Т.С., Козлов Р.С. Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследований. Клиническая микробиология и антимикробная химиотерапия. 2012; 14(4): 280-302.
  17. Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., Athanasiou S. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 2010; 65(9): 1862-77.
  18. Nicolle L.E., Bradley S., Colgan R., Rice J.C., Schaeffer A., Hooton T.M. Infectious Diseases Society ofAmerica guidelines for the diagnosis and treatment bacteriuria in adults. Clin. Infect. Dis. 2015: 40(5): 643-54.
  19. European Association of Urology. EAU Guidelines urological infections; update 2017; 3.4.5. Available at: www.uroweb.org
  20. Алиджанов Ж.Ф. Существуют ли альтернативные методы антибактериальной терапии и профилактики неосложненных инфекций мочевыводящих путей? Урология. 2014; 6: 5-13.
  21. Зайцев А.В., Колонтарев К.Б. Роль фосфомицина в лечении инфекций мочевыводящих путей. Урология. 2017; 4: 91-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies